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targeted prescription of chemotherapy with appropriate platinum com-
bination.
Authors would like to thank Barbora Belsanova for help with geno-
typing experiments. This work was supported by the Internal Grant 
Agency of the Czech Ministry of Health project number NR/9087-3.
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Background: Ethnic or racial differences in drug disposition (popula-
tion-related pharmacogenomics) may explain conﬂicting results of clin-
ical trials using similar treatment. We prospectively designed 3 separate 
phase III trials in advanced NSCLC (FACS & LC03 in Japan, S0003 in 
USA) with a paclitaxel-carboplatin “common arm” in order to compare 
outcomes. Differences in toxicity and efﬁcacy were noted between the 
2 Japanese studies and S0003 (Gandara, ASCO 05 & Crowley, ASCO 
06). We sought to determine whether these ﬁndings were due in part to 
PG alterations. 
Methods: Genomic DNA was prospectively collected from patients 
(pts) in 2 of these Phase III trials (LC03 [N=78, 37 on common arm] & 
S0003 [N=78]) with identical eligibility, staging, treatment paclitaxel 
(225mg/m2) & carboplatin (AUC 6), response & toxicity criteria. We 
analyzed for genotypic variants related to paclitaxel or platinum by 
pyrosequencing, & assessed results by Cox model for survival/PFS & 
logistics regression for response/toxicity.
Results: We will present an updated PG analysis for additional geno-
typic variants. There was a signiﬁcant difference between Japan & US 
pts in genotypes: CYP3A4*1b (p=.01), CYP3A5*3c (p=.03), ERCC2 
k751q (p < .001), and CYP2C8 r139k (p=.01). Genotypic correlations 
were observed between CYP3A4*1b for PFS (HR 2.75, 1.06-7.08, 
p=.04) & ERCC2 k751q for response (HR 0.33, 0.13-0.84, p=.02. For 
grade 4 neutropenia, the HR for ABCB1 3425c->T was 1.84 (0.77-
4.48), p=.19. 
Conclusions: 1) Japanese and US pts in these studies differed in al-
lelic distribution for genes involved in paclitaxel disposition or DNA 
repair. 2) Genotype-associated correlations were present for PFS 
(CYP3A4*1b) and response (ERCC2 k751q). 3) The small sample 
size limits interpretation of these data. 4) We will present plans for ad-
ditional prospectively designed trials exploring population-related PGs 
based on this common arm model. 
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Background: The International Adjuvant Lung Cancer Trial (IALT) 
demonstrated that adjuvant cisplatin-based chemotherapy increases 
the 5-survival rate by absolute 4% in patients with completely resected 
NSCLC. Selection of those patients who beneﬁt from chemotherapy 
would be of major clinical relevance. Clinical parameters such as age, 
gender or histology did not predict the beneﬁt of chemotherapy. Thus 
we initiated a translational research project termed IALT-Bio. The aim 
of this project is to study molecular biomarkers of tumors for their 
potential predictive values with regard to the effect of adjuvant chemo-
therapy on survival in IALT patients. 
Methods: Five groups of molecular biomarkers (19 markers in total) 
were studied: drug transporters, DNA repair, cell cycle regulators, sig-
nal transduction, apoptosis. Expression of biomarkers was determined 
by immunohistochemistry. Overall survival was analyzed with Cox 
models adjusted for clinical and pathological factors.
Results: Tumor specimens were collected from 867 patients from 28 
IALT centers. These patients represented 46% of all IALT patients and 
83% of the patients enrolled by the 28 centers. Collection of the tumor 
specimens of a world-wide clinical trial posed several problems includ-
ing ethical and logistic problems. All tumor specimens were pathologi-
cally examined and 783 samples were considered to be of sufﬁcient 
quality for further analyses. The laboratory analyses of the various bio-
markers were performed by several research groups. ERCC1 expres-
sion was shown to be of prognostic and predictive value. Patients with 
ERCC1-negative tumors beneﬁted (hazard ratio of death 0.65, 95% 
CI 0.5-0.86) from adjuvant chemotherapy, whereas no beneﬁt (hazard 
ratio 1.14, 95% CI 0.84-1.55) was seen in patients with ERCC1-posi-
tive tumors (p value for the comparison of the two hazard ratios: 0.009) 
(Olaussen KA et al., NEJM 2006, 355, 983). Similarly, absence of p27 
expression predicted beneﬁt of adjuvant chemotherapy (Filipits M et 
al., JCO 2007, in press). The corresponding hazard ratios were 0.66 
(95% CI 0.5-0.88) for patients with p27-negative tumors and 1.09 (95% 
CI 0.82-1.45) for those with p27-positive tumors, respectively (p value 
for the comparison of the two hazard ratios: 0.02). ERCC1 and p27 
were predictive independently of each other. When ERCC1 and p27 
were combined, the predictive values were further increased: the hazard 
ratios were 0.52 (95% CI 0.36-0.74) for patients with tumors nega-
tive for both biomarkers but 1.27 (95% CI 0.87-1.84) for those with 
tumors positive for both markers. These 2 groups comprised 58% of the 
patients. Multidrug resistance proteins (MRP1, MRP2) did not predict 
the outcome of adjuvant chemotherapy (Filipits M et al., manuscript 
submitted). Patients with FasL-negative tumors also beneﬁt from adju-
vant chemotherapy (Brambilla E et al., WCLC 2007). Analyses of other 
biomarkers including mutations of p53, k-ras and EGF receptor are still 
ongoing. Current research is attempting to validate these markers on 
patient populations from other adjuvant chemotherapy trials. 
Conclusions: Both ERCC1 and p27 are of predictive value in patients 
with completely resected NSCLC undergoing adjuvant cisplatin-based 
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS398
chemotherapy. If conﬁrmed on other patient populations, our ﬁndings 
should signiﬁcantly advance the clinical management of patients with 
completely resected NSCLC. 
The study was supported by an unrestricted grant from Eli Lilly.
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Background: Non-small-cell lung cancer (NSCLC) patients with 
locally advanced or metastatic disease at the time of diagnosis show 
marginal response to chemotherapy in terms of tumor shrinkage, time 
to progression and median survival. MAP4 and stathmin have been pre-
viously reported as potential markers of resistance to treatment based 
on microtubule-destabilizing agents.
Methods: In this multicenter study, we have used quantitative PCR to 
analyze the expression of MAP4, stathmin, beta-tubulin III, BRCA1 
and ERCC1 using mRNA isolated from peripheral blood samples of 51 
non-small-cell lung cancer patients treated with vinorelbine/carboplatin.
Results: In a preliminary set, 46 patients with stage IIIB and IV 
were analyzed. Lower levels of MAP4/OP18 mRNA expression are 
statistically associated with a response to vinorelbine-based treatment 
(p=0.029). This signiﬁcant relationship is maintained in a second analy-
sis after 3rd cycle of treatment (p=0.032). Higher levels of MAP4/op18 
were associated with a lower TTP (p=0.05).
Conclusions: Our preliminary results suggest that the ratio MAP4/
OP18 may be a good predictor of response for NSCLC patients treated 
with vinorelbine-based chemotherapy.
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Objective: To prospectively evaluate the use of positron emission 
tomography (PET) with the glucose analog 18-ﬂuorodeoxyglucose 
(18FDG) to predict best objective response and survival after the ﬁrst-
line chemotherapy in patients with advanced non-small cell lung cancer 
(NSCLC).
Methods: Patients with advanced NSCLC were prospectively enrolled 
into this study to undergo platinum-based doublet chemotherapy. 
Patients were studied by 18FDG-PET before and after the ﬁrst two 
cycles of chemotherapy. A reduction of tumor 18FDG uptake by more 
than 30% as assessed by standardized uptake value(SUV) was used as 
a criterion for a metabolic response. Compare RECIST response with 
18FDG-PET metabolic response by Measure of Agreement Kappa test.
Survival in patients with or without a metabolic response was com-
pared by the log-rank test. Statistical computations were performed 
with SPSS13.0. 
Results: 46 patients with advanced NSCLC (2 cases with wet stage 
IIIB and 44 cases with stageIV) were included in the study. There was 
a close correlation between metabolic response and best objective 
response to the ﬁrst-line chemotherapy according to RECIST, P<0.001; 
Sensitivity, speciﬁcity, accuracy, prediction of positive value and pre-
diction of negative value for prediction of best objective response were 
95%, 65%, 78%, 69% and 94% respectively. By the end of February 
28, 2007, duration of follow-up had been ranged from 1.8 months to 
29.7 months, median survival time for metabolic responders was 13.70 
months, 95% CI (9.08~13.32), and that for metabolic non-responders 
was 12.00 months, 95% CI (6.58~17.43), P >0.05; there is no differ-
ence in overall survival between metabolic responders and metabolic 
non-responders, P >0.05. 
Conclusions: Reduction of SUV in 18FDG-PET after two-cycle 
chemotherapy for advanced NSCLC is closely correlated with best 
objective response. However, up till now, we have not yet observed 
signiﬁcant difference in median survival time and overall survival time 
between metabolic responders and metabolic non-responders.
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Background: The treatment of non-small-cell lung cancer (NSCLC) 
has reached a plateau of effectiveness, but the selection of patients ac-
cording to key genetic characteristics may help to tailor chemotherapy 
and optimise the treatment increasing response rates and survival. Poly-
morphisms within the Xeroderma Pigmentosum Group D (XPD), Exci-
sion Repair Cross-Complementing 1 (ERCC1) and Cytidine Deami-
nase (CDA) genes have been associated with alterations in enzymatic 
activity and may change sensitivity to the widely used platinum-based 
and gemcitabine chemotherapy regimens. We investigated the correla-
tion between selected single nucleotide polymorphisms (SNPs) of these 
genes and the activity and efﬁcacy of chemotherapy.
Methods: Seventy-eight chemotherapy-naïve, advanced NSCLC 
patients were enrolled in the study; 52 were treated with cisplatin/gem-
citabine and 26, aged > 70 years, with gemcitabine alone. Median age 
was 66 years (range 44-81). Association between XPD Asp312Asn and 
Lys751Gln, ERCC1 C118T and CDA Lys27Gln SNPs and treatment 
response, toxicity, time to progression (TTP) and overall survival (OS) 
was estimated using Kaplan-Meier method, Log-rank test and Cox’s 
proportional model. SNPs were analyzed with the ABI PRISM 7900HT 
Sequence Detection System using TaqMan® probe-based assay in DNA 
obtained from peripheral blood samples.
